The Post-Ozempic Economy? 2 Industries Bracing for a Slimmer, Less Hungry America

Weight-loss drugs are being framed as a consumer-spending disruptor: they may pressure restaurant demand, with Chipotle reporting flat to negative same-store sales growth for four straight quarters and its stock down 50% from highs. At the same time, fitness could benefit, with Planet Fitness revenue up 171% cumulatively over five years, 2025 same-club sales up 6.7%, and 1.1 million new members added. The article argues that GLP-1 adoption, new oral pills, and next-generation drugs like retatrutide could permanently shift spending from dining out toward fitness.

Analysis

GLP-1 adoption is less a simple “less food, more gym” trade and more a capital reallocation shock: dollars migrate out of impulse-heavy, high-frequency discretionary spend and into recurring health/wellness baskets with higher perceived ROI. That transition is asymmetric because restaurants face immediate traffic elasticity while fitness monetization usually lags through membership growth, retention, and ancillary spend. The second-order winner is likely not just gym operators but also adjacent categories that benefit from longer engagement cycles: protein brands, recovery, sportswear, and at-home wellness equipment.

For CMG specifically, the market may be underestimating how much of the pressure is mix, not only traffic. If GLP-1 users compress lunch baskets and reduce add-ons, same-store sales can look “fine” for a while while unit economics quietly deteriorate through lower ticket and weaker premiumization. That makes the next few quarters more important than the next few years: a sustained earnings reset is possible before management can fully re-engineer the menu toward high-protein, higher-margin bundles.

PLNT is the cleaner beneficiary because it monetizes the behavior shift multiple times: initial membership, low churn from habit formation, and upside from consumers treating fitness as part of a medicalized weight-loss regimen rather than pure lifestyle spend. The risk is valuation and over-earning a structural theme too early; if the GLP-1 adoption curve pauses, PLNT can still work, but the multiple likely compresses first. The broader contrarian point is that the market may be overfocusing on restaurant damage and underpricing winners in the rest of the consumer ecosystem that absorb the freed-up spend.

Key Decisions for Investors

• Maintain a tactical short bias in CMG over the next 1-2 quarters via put spreads or a covered short-call structure; the setup favors slow-burn multiple compression more than an immediate collapse, so structure for time decay rather than outright downside chase.
• Go long PLNT on pullbacks with a 6-12 month horizon; pair it against a weaker discretionary consumer basket to isolate the GLP-1-driven demand shift while reducing market beta.
• Add a basket long of fitness/protein adjacency names rather than only gym operators; the highest convexity is in businesses that monetize the lifestyle change across multiple purchase occasions.
• Avoid assuming the restaurant decline is permanent in every concept; prefer shorting low-differentiation chains with weak menu flexibility rather than quality operators that can pivot to high-protein offerings.
• If CMG underperforms into the next earnings cycle, consider a pair trade long PLNT / short CMG to express the consumer-spend reallocation theme with cleaner relative fundamentals and better risk control.